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xbstract Here we report the isolation and characterization of 
:m antibacterial peptide from bovine milk inhibiting the growth 
~,f Escherichia coli, and Staphylococcus carnosus. The primary 
~tructure of the peptide was revealed as a 39-amino-acid-contain- 
ing fragment of bovine as2-casein (position 165-203) by means of 
Edman amino acid sequencing and mass spectrometry. Since 
human milk does not contain any casein-asz, these findings could 
explain the different influence of human and bovine milk on the 
,4astrointestinal flora of the suckling. 
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I. Introduction 
The occurrence of  certain bacterial species in milk indicates 
the existence of specific factors influencing bacterial growth. 
Another finding is that the intestinal flora of the newborn 
mainly depends on the source of the ingested milk [1]. Breast- 
fed sucklings, for example, almost exclusively exhibit Bi- 
fidobacterium bifidum in their intestine [2]. Milk proteins which 
are supposed to be responsible for this modulation are for 
example lysozyme [3,4], lactoperoxidase [5-7], lactoferrin [7-9] 
and antibodies [10]. However, in vivo the ingestion of lactofer- 
rin has only a marginal influence on the intestinal microflora 
[1 1]. Moreover, it was shown that different effects on the micro- 
bial growth can be obtained by applying certain dietary formu- 
lations of milk proteins [11]. 
In the last few years, the research on antimicrobial peptides 
like defensins has come into focus [12]. These peptides were first 
identified in insects [13] and are also present in lower verte- 
brates and in mammals. Antimicrobial peptides are mainly 
stored in cytoplasmic granules of specialized leukocytes [14] but 
the presence of these factors could also be demonstrated in
intestinal Paneth cells of mice (cryptdins) and man (defensins), 
indicating a possible role in the regulation of the local bacterial 
flora [15-19]. Another aspect is that several antimicrobial pep- 
tides present in ruminants are not found in other mammalian 
species, possibly correlating with the different anatomy and 
physiology of their gastrointestinal system [20,21]. 
The aim of this study was to investigate whether peptides 
capable of modulating the composition of the intestinal flora 
are present in bovine milk. In a whey fraction we were able to 
detect a heat and acid-stable antibacterial property against 
E. coli. Further purification and characterization revealed a 
39-amino-acid-containing fragment derived from casein-~2 to 
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which we refer as casocidin-I. Many bioactive peptides have 
earlier been identified as digestion products of caseins. Some 
of them behave like opioids, immunomodulators or enzyme 
inhibitors. Others have antithrombotic activities or act as min- 
eral carriers [22-24]. 
2. Experimental 
2.1. Treatment oJ milk 
Grade A bovine milk (Heirler, Darmstadt, Germany; 1.5 litres of 
controlled quality) was purchased from a local health-food shop. Gla- 
cial acetic acid was added to a final concentration f 10% (v/v) and the 
milk was subsequently boiled for 5 min. It was then cooled to 50 ° C 
and 1 g/1 CaCI2.2H20 was added. To block serine proteases we used 
50/IM phenylmethylsulfonate. After centrifugation (15 min, 3500 x g 
at 4°C) the resulting supernatant was collected, diluted with 4 volumes 
of water and incubated with 25 ml of a strong cation exchange resin 
(Parcomer; 20 ~tm, Biotek, Heidelberg, Germany). The resin was 
washed with 250 ml of 5 M urea in 5 mM phosphate buffer (pH 3.0) 
and with 250 ml water. To elute bound peptides we applied 100 ml of 
1 M NaCI in 5 mM phosphate buffer (pH 3.0) at room temperature. 
The eluate was centrifuged (5 min, 1000 x g, RT) and residual resin 
particles were removed by means of filtration through a 0.2/~m dispos- 
able syringe filter (Sartorius, G6ttingen, Germany). 
2.2. Antibacterial assay 
Column fractions were tested against Escherichia coli XL1 blue 
(Stratagene, Heidelberg, Germany), Escherichia coli BL21 (DE3) and 
Staphylococcus carnosus TM300 (a gift from F. Goetz, Technical Uni- 
versity of Munich, Germany) by a sensitive radial diffusion technique 
as described [25]. We used agarose without EEO (Serva, Heidelberg, 
Germany) either in 25 mM phosphate (pH 7.2) or Tris-HC1 (pH 7.4). 
2.3. HPLC purification 
The HPLC purification steps were performed on Parcosil-C~8 
( 1 x 12.5 cm, 100 A, 5/lm) and Parcosil-C4 (0.4 x 12.5 cm, 300 A, 5/am) 
reversed-phase columns (Biotek, Heidelberg, Germany). A HPLC sys- 
tem (Kontron, Miinchen, Germany) equipped with two model 420 
pumps, a model 432 fixed-wavelength detector (214 nm or 280 nm) and 
a model 450 data system was used. After equilibration with 0.1% TFA, 
peptides were eluted by linearly increasing the amount of solvent B 
(acetonitrile with 0.1% TFA) as follows: gradient 1= 0-50 min, 0-80% 
B; gradient 2 = 0-5 min, 0 15% B; 5-65 min, 15 80% B; gradient 
3 = 0- 5 rain, 0 15% B; 5-65 min, 15-80% B. 
2.4. Proteolytic cleavage 
Proteolytic leavage was performed with trypsin, pronase or en- 
doproteinase Glu-C in 25 mM Tris-HCl, pH 7.0, at a protease-to- 
peptide ratio of 1 : 100 (w/w). The reactions were stopped by heating at 
95°C for 5 min. Samples without enzyme were used as controls. 
2.5. Peptide analysis 
Amino acid sequence determinations were carried out automatically 
on an Applied Biosystems 473 A gas phase sequencer (Applied Biosys- 
terns Div. of Perkin Elmer, Weiterstadt, Germany). 
2.6. Capillary zone electrophoresis 
Capillary zone electrophoresis (CZE) was performed with a 50 cm 
uncoated capillary of fused silica on the CZE system model PLACE 2100 
(Beckmann, Miinchen, Germany). The running buffer used was 100 
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mM NaH~PO4, pH 2.5, containing 0.02% hydroxypropylmethylcellu- 
lose. After injection of 60 nl sample, the separation was carried out with 
a constant current of 120 etA. 
2. 7. Mass spectrometric, analysis (MS) 
Mass spectrometric analysis (MS) was performed on a triple-stage 
quadrupole lectrospray mass spectrometer Sciex API III (Perkin 
Elmer, Ueberlingen, Germany) equipped with an articulated ion-spray 
source operating at atmospheric pressure. The lyophilized samples were 
dissolved in 50% acetonitrile/0,2% acetic acid prior to injection. Mass 
spectra were recorded in positive ion mode. For the HPLC-MS analy- 
sis, a reversed phase C~8 column (YMC, Schermbeck. Germany, 
1 mmx 250 ram, 120 A, 3pro) and the mass spectrometer were coupled• 
Direct coupling of HPLC with the mass spectrometer was performed 
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using a model 140B double syringe pump, and a model 740B UV- 
detector equipped with the capillary flow cell (Applied Biosystems Div. 
of Perkin Elmer, Weiterstadt, Germany). The flow rate was 20 pl/min 
using a linear gradient starting with 0.06% TFA increasing the eluent 
B (80% acetonitrile with 0.05% TFA) by 1% per minute. The column 
outlet was directly connected with the ion spray using a 50 ,urn fused 
silica capillary without post column splitting. 
2.8. Chemical synthesis 
Chemical synthesis ofpeptides was carried out as described elsewhere 
[26,27]. The purification was performed on a Vydac RP-C~8 column 
(MZ-Analysentechnik, Mainz, Germany; 10pm, 300 A,, 2 x 25 cm) with 
0.06% TFA/acetonitrile/water at a flow rate of 10 ml/min. The purity 
was controlled by means of HPLC, CZE and mass spectrometry• 
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Fig. 1. Purification of casocidin-I. (a, top) The eluate of the cation exchanger equivalent to 350 ml whey was chromatographed on a Parcosil C-18 
column using gradient 1. (a, bottom) The growth inhibitory activity of the eluate was monitored with E. coli XL-I blue as described in methods. 
The radius of the growth inhibition zone sorrounding the wells was measured. (b) The most active fraction 7 was rechromatographed applying radient 
2 on the same column. Antibacterial fractions are shaded. Fraction 13 is further processed. (c) RP-C4 chromatography of fraction 13 using gradient 
3. The active fraction 8 is seen in the hatched zone. (d) CZE analysis of fraction 8 containing casocidin-l. 
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Fig. 2. Amino acid sequence of casocidin-I. Casein-~2(165-203) in the 
,.ne letter code. Basic residues are typed in boldface. 
~. Results and discussion 
~. 1. Purification of casocidin-I 
In order to denature and to clear away most of the high 
nolecular weight proteins, we initially treated the milk by boil- 
ng and mild acidifying. Additionally, calcium chloride was 
tdded to precipitate calcium-dependent phosphoproteins [28]. 
Fat and coagulated proteins were removed by means of centrif- 
agation, the resulting volume of the supernatant was about 
56%. To concentrate basic peptides, a cation exchange step was 
performed as described above. For further purification of the 
antibacterial peptides, we combined different reversed-phase 
HPLC separation procedures. For the first separation step a 
Parcosil C~8 RP column was used and an amount of 350 ml 
whey (Fig. la) was applied. The bactericidal activity of an 
aliquot equivalent o 8.8 ml whey was monitored, and the 
maximum activity could be detected in fraction 7 (Fig. la). 
Lower levels could also be detected in adjacent fractions and 
in fraction C. Prior to purification procedures we performed 
some controls: lysozyme activity was monitored with a Micro- 
coccus lysedeicticus cell wall suspension and the presence of 
fl-lactam antibiotics was excluded using bacteria carrying the 
Fig. 3. Growth inhibition test with Staphylococcus carnosus TM300. 
Each well was loaded with 10 #1 sample containing various amounts 
of casocidin-I. The arrow indicates the direction of the increasing pep- 
tide dosage (range 0 ng, 100 ng, 200 ng, ... 1400 ng peptide). The 
diameter of each well is 3 mm. The dark areas correspond to the dose 
dependent zones of growth inhibition after application of synthetic 
casocidin-1. 
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Fig. 4. LC-MS analysis of the active fraction 7 from Fig. |a. The dotted 
line shows the reconstructed ion current profile. Open circles indicate 
position and mass of several molecules. Solid diamonds represent ca- 
sein-~2 masses tarting with residue 165 or 166. 
plasmid pUC-18. At least we were able to eliminate the anti- 
bacterial activity with trypsin or pronase indicating that it was 
coupled to a polypeptide. Thus, further purifications were con- 
ducted. The second step of purification was performed with the 
same RP-C~s column using a less steep gradient (Fig. lb). Here 
we tested the eluate for the presence of antibacterial ctivity 
which eluted over a broad range in fractions 13-15. Further 
HPLC purification steps using fractions 14 and 15 could resolve 
several peaks but resulted in the loss of activity. In the third step 
of purification, the antibacterial ctivity of fraction 13 could be 
recovered by RP-C 4 HPLC (Fig. lc). This appeared in fraction 
8, whereas fraction 4, representing a dominant peptide-contain- 
ing peak, exhibited no inhibitory effect. 
3.2. Characterization of casocidin-I 
CZE analysis revealed a dominant compound with high pu- 
rity (Fig. ld) sufficient for amino acid sequence and mass spec- 
trometric analysis. The peptide was identified as a 39-amino- 
acid-containing casein-~2 fragment (position 165-203) of 4870 
Da which we refer to as casocidin-I (Fig. 2). Both terminal 
amino acids of the peptide represent potential tryptic cleavage 
sites. Moreover, the N-terminal lysine is located in a dibasic 
lysine motif appearing in the precursor molecule. The calcu- 
lated pl of this peptide is 8.9 and a hydrophobicity-plot shows 
a regular alternation of hydrophobic and hydrophilic residues. 
This gives rise to the hypothesis that the mechanism of action 
resembles that of amphiphatic defensins permeabilizing bacte- 
rial membranes. Casein-~2 is not present in human milk and 
so we propose that casocidin-I or related peptides of bovine 
milk influence the human intestinal flora, particularly of the 
suckling. 
3.3. Antibacterial activity of synthetic asocidin-I 
In order to demonstrate hat the activity was due to caso- 
cidin-I and not to accompanying impurities, we chemically syn- 
thesized casein-~(165-203). Subsequently performed bioas- 
says showed that the synthetic peptide also exhibits an anti- 
bacterial effect. Using E. coli XL1 blue, E. coli BL21, and 
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Staphylococcus carnosus TM300 casocidin-I induces a dose de- 
pendent zone of growth inhibition in the used assay (Fig. 3). 
S. carnosus appeared to be more sensitive than E. coil Here, 
only 1/10 of casocidin-I is necessary to generate comparable 
growth inhibitory effects. The antibacterial properties vanished 
after degradation with trypsine but not after treatment with 
endoproteinase Glu-C. So the glutamate residues near the N- 
terminus did not seem to be essential for the growth inhibition. 
3.4. HPLC-MS analysis of active fractions 
To estimate the number of peptides, and the presence of 
casocidin-related peptides in the starting fraction 7 we applied 
a high resolution Cl8 reversed phase HPLC separation step 
coupled with the quadrupole ion spray mass spectrometer as
a detector (HPLC-MS analysis). By use of this method we 
detected several distinct masses appearing in the elution profile. 
To prove our assumption that peptides homologous to caso- 
cidin-I, possibly sharing the same antibacterial property, were 
present in fraction 7, we computed the compound masses of 
hypothetical casein-e~2-derived fragments beginning with resi- 
due 165 or 166. We were able to identify a large number of the 
corresponding masses (Fig. 4). For example, the mass for the 
complete C-terminal portion of casein-c~z was also detectable. 
We assume that these fragments together combine their anti- 
bacterial activity. The difficulty in recovering the activities of 
certain subfractions might have been due to the large number 
of only slightly differing molecules, each present in a lower 
amount han the detection limit of the bacterial growth inhibi- 
tion assay. 
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